Document is current
Any future updates will be listed below
-
Authors
Ding, Bo https://orcid.org/0000-0001-9131-4563
Pignot, Marc https://orcid.org/0000-0002-1883-4113
Garal-Pantaler, Elena https://orcid.org/0009-0005-5285-6913
Villinger, Beate
Schefzyk, Sebastian
Desta, Barnabas https://orcid.org/0000-0001-6928-2294
Stirnadel-Farrant, Heide A. https://orcid.org/0000-0003-0734-0422
Schwarting, Andreas https://orcid.org/0000-0002-0566-598X
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 10 October 2023
Accepted: 20 December 2023
First Online: 22 January 2024
Declarations
:
: Andreas Schwarting has received research grants from Novartis, GSK, and Roche; consulting fees from Kantar Health, and honoraria for presentations from GSK, Novartis, and AstraZeneca. Heide A. Stirnadel-Farrant has stock or stock options in GSK. Barnabas Desta, Bo Ding, and Heide A. Stirnadel-Farrant are employees of AstraZeneca and have AstraZeneca stock or stock options. Sebastian Schefzyk is an employee of AstraZeneca. Marc Pignot is an employee of ZEG-Berlin, which was funded by AstraZeneca to conduct the study. Elena Garal-Pantaler is an employee of Team Gesundheit GmbH, Essen, Germany, which was sub-contracted by ZEG-Berlin. Beate Villinger is a consultant of AstraZeneca.
: All patients who met inclusion criteria were included in the study. Use of the BKK database for health services research is fully compliant with German federal law; health insurance companies were informed of the project, and required approvals were received from BKK. The study conformed with the Helsinki Declaration of 1964, as revised in 2013, concerning human and animal rights. Informed consent by patients was not necessary and institutional review board/ethical approval was not required, as these claims data are de-identified.
